Stay updated on Pembrolizumab in Poor-Prognosis CUP Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:21:10.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the total number of trial subjects for the study involving Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP). This change reflects an adjustment in the estimated enrollment period and duration of the trial, potentially impacting the study's progress and outcomes.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:02.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    50%
    Check dated 2024-05-22T20:24:58.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T23:00:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Poor-Prognosis CUP Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page.